PD-1/PD-L1 and TLR Combination Therapy for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immune checkpoint inhibitor monotherapy for cancer treatment has poor efficacy due to immunosuppressive tumor microenvironments and insufficient T cell activation, leading to therapeutic drug resistance.
Innovation Solution
A pharmaceutical combination of an immune checkpoint inhibitor (PD-1/PD-L1) and a Toll Like Receptor (TLR) agonist, such as an imidazole quinoline derivative, to relieve inhibitory signals, enhance T cell activation, and induce cytokine expression, thereby promoting both adaptive and innate immune responses against tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If immune checkpoint inhibitor monotherapy is used, then treatment simplicity is maintained, but therapeutic efficacy is insufficient due to immunosuppressive tumor microenvironment and T cell activation deficiency
Solution Approach 1:
The patent combines immune checkpoint inhibitors with TLR agonists into a unified treatment regimen. The TLR agonist component activates innate immune cells ( dendritic cells, macrophages, NK cells) to enhance anti-tumor immunity, while the immune checkpoint inhibitor removes inhibitory signals. This merging of two mechanisms addresses the insufficiency of monotherapy by simultaneously boosting immune activation and reducing immunosuppression in the tumor microenvironment.
Solution Approach 2:
The TLR agonist acts as an intermediary that bridges innate and adaptive immunity. By activating TLRs on dendritic cells and other immune cells, it enhances the presentation of tumor antigles to T cells, thereby amplifying the effect of the immune checkpoint inhibitor. This intermediary mechanism allows the combination to overcome the limitations of monotherapy more effectively.
2Device complexity
If immune checkpoint inhibitor monotherapy is used, then treatment protocol simplicity is maintained, but T cell activation is insufficient leading to therapeutic drug resistance
Solution Approach 1:
The combination regimen merges TLR agonist-mediated innate immune activation with immune checkpoint inhibition. The TLR agonist component specifically targets and activates T cells and other immune cells, providing an additional activation mechanism beyond what immune checkpoint inhibitors alone can achieve. This merging directly addresses the insufficient T cell activation and resulting therapeutic resistance.
Solution Approach 2:
The TLR agonist performs preliminary activation of the innate immune system before and during the action of the immune checkpoint inhibitor. By pre-activating dendritic cells, macrophages, and NK cells through TLR signaling, the system creates a more responsive immune environment that enhances subsequent T cell activation and overcomes therapeutic resistance more effectively.
Data Source
AI summary
A pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a PD-1 inhibitor and/or a PD-L1 immune checkpoint inhibitor; and a Toll Like Receptor (TLR) agonist.